节点文献
新型口服抗凝药的药物基因组学研究现状
Research status on pharmacogenomics of new oral anticoagulants
【摘要】 口服抗凝药是预防或治疗血栓栓塞性疾病的有效措施,相比于传统口服抗凝药华法林,新型口服抗凝药因具有抗凝效果相当,使用方便,且安全风险低等特点,近年来在临床上应用广泛,伴随临床使用及研究发现,新型口服抗凝药的抗凝治疗存在较大的个体差异。因此,本文对新型口服抗凝药的药理作用、药代动力学特征以及药物基因组学研究现状做一综述,以期为新型口服抗凝药的个体化治疗研究提供参考。
【Abstract】 Oral anticoagulant is an effective measure to prevent or treat thromboembolic diseases. Compared with the traditional oral anticoagulant warfarin,the new oral anticoagulants have the characteristics of same anticoagulant effect,easy to use,and low safety risk,therefore have been widely used in clinical practice in recent years. With clinical use and research,there are large individual differences in anticoagulant therapy for new oral anticoagulants. We reviewed the pharmacological effects,pharmacokinetics and pharmacogenomics of new oral anticoagulants in order to provide reference for individualized treatment of new oral anticoagulants.
【Key words】 new oral anticoagulant; pharmacokinetics; pharmacogenomics; gene polymorphism;
- 【文献出处】 中国临床药理学杂志 ,The Chinese Journal of Clinical Pharmacology , 编辑部邮箱 ,2019年18期
- 【分类号】R96
- 【被引频次】2
- 【下载频次】445